Previous 10 | Next 10 |
2023-11-13 10:25:01 ET More on Iterum Therapeutics Seeking Alpha’s Quant Rating on Iterum Therapeutics Historical earnings data for Iterum Therapeutics Financial information for Iterum Therapeutics For further details see: Iterum Therapeutics Q3 20...
2023-11-13 09:41:06 ET Major earnings expected before the bell on Tuesday include: Canadian Solar ( CSIQ ) The Home Depot ( HD ) Sea ( SE ) Vodafone Group Public ( VOD ) Workhorse Group ( WKHS ) For further details see: Notable earnings be...
DUBLIN, Ireland and CHICAGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community...
– Topline Data Expected in Early Q1 2024 – – NDA Resubmission Expected in Q2 2024 – DUBLIN, Ireland and CHICAGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company f...
DUBLIN, Ireland and CHICAGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community...
2023-08-11 09:20:06 ET Iterum Therapeutics plc (ITRM) Q2 2023 Earnings Conference Call August 11, 2023 8:30 AM ET Company Participants Louise Barrett - Senior Vice President, Legal Affairs Corey Fishman - Chief Executive Officer Judy Matthews - Chief Financial Of...
2023-08-11 07:08:32 ET Iterum Therapeutics press release ( NASDAQ: ITRM ): Q2 GAAP EPS of -$0.95 misses by $0.15 . Cash, cash equivalents and short-term investments were $44.7 million as of June 30, 2023. Based on its current operating plan, Iterum expects that its cur...
-- Expect to Complete Enrollment in Q1 2024; Topline Data Expected in Q2 2024 -- -- Cash Runway into Q3 2024-- DUBLIN, Ireland and CHICAGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on dev...
DUBLIN, Ireland and CHICAGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community...
DUBLIN, Ireland and CHICAGO, June 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community...
News, Short Squeeze, Breakout and More Instantly...
Iterum Therapeutics plc Company Name:
ITRM Stock Symbol:
NASDAQ Market:
Iterum Therapeutics plc Website:
A look at the top 10 most actives in the United States Conduit Pharmaceuticals Inc. (CDT) rose 40.0% to $0.3361 on volume of 63,970,490 shares Yoshitsu Co. Ltd (TKLF) rose 64.0% to $0.5024 on volume of 62,618,792 shares Silo Pharma Inc. (SILO) rose 91.8% to $2.0522 on volume of 59,055,593...
DUBLIN, Ireland and CHICAGO, June 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community...
DUBLIN and CHICAGO, June 05, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hosp...